Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

932
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
932
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.5K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.5K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

540
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
540
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

407
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
407
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.5K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

676
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
676

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual and joint association of Life's Essential 8 metrics with pre-sarcopenia among U.S. adults.

BMC musculoskeletal disorders·2024
Same author

Cervical lymph node metastasis prediction from papillary thyroid carcinoma US videos: a prospective multicenter study.

BMC medicine·2024
Same author

[Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF<sup>V600E</sup> Mutation in Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2024
Same author

Elevated plasma pyruvate kinase M2 concentrations are associated with the clinical severity and prognosis of coronary artery disease.

Biochemia medica·2023
Same author

The CONUT score predicts the length of hospital stay and the risk of long COVID.

Nutricion hospitalaria·2023
Same author

[Effect of Calcification on the Ultrasound-Guided Radiofrequency Ablation of Papillary Thyroid Carcinoma].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2023

Related Experiment Video

Updated: Mar 21, 2026

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

15.8K

Elevated endocan concentration is associated with coronary slow flow.

Ming-Fang Ye1, Zi-Wen Zhao1, Yu-Kun Luo1

  • 1a Department of Cardiology , Union Hospital, Fujian Medical University, and Fujian Institute of Coronary Artery Disease , Fuzhou , P. R. China.

Scandinavian Journal of Clinical and Laboratory Investigation
|May 17, 2016
PubMed
Summary

Serum endocan levels are higher in patients with coronary slow flow (CSF). Elevated endocan is linked to CSF presence and severity, suggesting it may be a useful biomarker for this condition.

Keywords:
Coronary artery diseasebiomarkercoronary slow flowendocanendothelial dysfunction

More Related Videos

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.6K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Experiment Videos

Last Updated: Mar 21, 2026

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

15.8K
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.6K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Area of Science:

  • Cardiology
  • Biomarkers
  • Vascular Biology

Background:

  • Coronary slow flow (CSF) is a condition affecting coronary artery blood flow.
  • The role of specific biomarkers in CSF is an area of ongoing research.
  • Endocan, a proteoglycan, has been implicated in vascular inflammation.

Purpose of the Study:

  • To investigate the association between serum endocan concentration and coronary slow flow (CSF).
  • To determine if serum endocan levels can serve as a predictive biomarker for CSF.
  • To explore the correlation between endocan levels and the severity of CSF.

Main Methods:

  • Serum endocan concentration was measured using enzyme-linked immunosorbent assay (ELISA).
  • Coronary slow flow (CSF) was diagnosed using the thrombolysis in myocardial infarction (TIMI) frame count (TFC) method.
  • Statistical analyses, including multivariate logistic regression, were employed to assess associations.

Main Results:

  • Serum endocan concentration was significantly higher in patients with CSF compared to controls (1.03 vs. 0.80 ng/mL, p=0.002).
  • Higher serum endocan levels were independently associated with the presence of CSF (OR 1.774, p=0.028).
  • Serum endocan concentration showed a positive correlation with mean-TIMI frame count (r=0.289, p=0.005) in CSF patients.

Conclusions:

  • Serum endocan may be a valuable biomarker for predicting the presence and severity of coronary slow flow.
  • Further research is warranted to explore therapeutic strategies targeting endocan to manage CSF progression.
  • Down-regulating endocan could potentially be a future therapeutic approach for CSF.